Atopic eczema is a life-long skin condition, so the main aim of treatment is to improve symptoms and achieve long-term control
Atopic eczema (AE), also known as atopic dermatitis, is a common, non-communicable, chronic, inflammatory skin condition characterised by intense itch and recurring eczematous lesions. AE is the most common inflammatory skin disorder in children and infants, affecting approximately 20 per cent of children. However, for some, AE can persist or develop for the first time in adulthood, with some reports suggesting up to 10 per cent of adults are affected. Clinical manifestations (appearance and location of eczematous lesions) of AE may vary with age, and three stages have been recognised — infancy, childhood, and adolescent/adult.
Depending on severity, this inflammatory skin condition is recognisable by severe dryness caused by a dysfunctional epidermal barrier, intense itching, cutaneous inflammation, and vesicle formation. AE symptoms have a chronic or relapsing disease course. As itch is a major symptom of AE, scratching only provides temporary relief and leads to more itching and scratching, which is often referred to as the ‘itch-scratch cycle’. The clinical appearance of AE may be modified by scratching, which in time may produce lichenification, broken skin surface resulting in excoriations, exudate, and secondary infection.
Pathophysiology and risk factors
The pathogenesis of this common inflammatory skin disease is complex and comprises an interplay of genetics, immunologic and environmental triggers that lead to a skin barrier disruption and abnormal immune system response.
A strong risk factor for AE is a positive family history and in excess of 30 susceptibility loci have been identified in genome-wide association studies. The strongest known genetic risk factor in AE is associated with null (loss-of-function) mutations in filaggrin gene (FLG), which encodes a key epidermal structural protein filaggrin (FLG), which is necessary for skin barrier function.
The epidermis acts as a barrier, preventing water loss, as well as entry of foreign substances such as irritants, microbes, and allergens. The epidermal barrier is made up of structural proteins, including FLG. FLG deficiencies or mutations in the epidermis result in a weakened skin barrier, as it is less able to retain water, and the lipids that surround and support the cells break down more quickly.
The impaired skin barrier allows loss of moisture and irritants or allergens to pass through the skin more easily. This can ultimately prompt an inflammatory cascade. The immune response, which involves T-helper cell (Th) type 2 and other T-cell subsets, results in greater activity of interleukins (IL)-4, IL-5, and IL-13 in both acute and chronic disease, which contribute to further changes, which include activation of eosinophil and mast cells, B-cell IgE production and IL-31 secretion. This series of events is thought to lead to itch and further disruption to the skin barrier due to scratching.
Triggers of AE may include allergen exposure, such as house dust mites, whereas non-allergic factors such as Staphylococcus aureus infection, abrasive garments, temperature changes, stress, and exposure to irritants such as detergents, harsh soaps and fragrances and habitual scratching can disrupt the skin barrier function.
Assessment and management of atopic eczema
Once a diagnosis of AE is established, treatment decisions are based on disease activity and impact of the disease on the patient’s quality of life. According to UK NICE guidelines, referral to dermatology specialist consultation is recommended if: A child’s eczema is uncontrolled or unresponsive, including recurring infections; and/or a negative impact on quality-of-life and psychosocial wellbeing.
The diagnosis of AE is made clinically and is based on clinical features, the patient’s history, and exclusion of other dermatoses. Occasionally, skin biopsy, blood tests and patch testing may be useful to rule out other skin conditions. The overall disease severity may be determined by using formal diagnostic criteria, of which several sets have been developed over time. One of the most acknowledged diagnostic criteria is the Hanifin and Rajka criteria.
A scientific refinement of the Hanifin and Rajka criteria was developed by the UK Working Party criteria. According to the UK Working Party diagnostic criteria, a diagnosis for AE requires that patients must have a history of itchy skin, plus a minimum of three of the following:
The European Task Force on Atopic Dermatitis developed the Scoring of Atopic Dermatitis (SCORAD) scale, which combines evaluation of extent, intensity of skin lesions, and symptoms such as day-time itch and sleep loss. AE that scores above 50 is categorised as severe, while values below 25 are regarded as mild.
Other disease severity scales used are the Eczema Area and Severity Score (EASI), which only assesses the visible lesions’ extent and severity and not subjective symptoms, such as sleep disturbance and itch. In contrast, the Patient-Orientated Eczema Measures (POEM) is a symptoms-only score, measuring subjective symptoms and frequency from a patient’s perspective.
A really useful health-related quality-of-life measurement tool used in clinical practice is the Dermatology Life Quality Index (DLQI). This tool is not AE-specific, however it helps clinicians to assess the impact of AE on the person’s life and assists the clinician to measure effectiveness of treatments. DLQI scores range from 0 (no impairment of quality of life) to 30 (maximum impairment).
For children, there is the Children’s Dermatology Life Quality Index (CDLQI), which also consists of 10 questions, with four possible replies, and the scores also range from 0-to-30. The aim of the questionnaire is to measure how much the child’s skin condition affected them in the last week.
AE is a life-long skin condition, so the main aim of treatment is to improve symptoms and achieve long-term control. Although there is no cure yet, typically a multi-step treatment approach is considered, according to severity of the disease, patient age, and its extent and distribution.
The key principles in AE management are: Restoring the skin barrier with emollient therapy; baseline trigger avoidance; and anti-inflammatory treatment with topical steroids or topical calcineurin inhibitors (non-steroidal immunomodulators). When topical treatments do not provide relief of symptoms, or in severe cases of AE, phototherapy may be considered, and lastly, systemic immunosuppressants may be prescribed.
Ongoing efficacious, practical application of over-the-counter emollients is the cornerstone of treatment for the condition (augmented by topical corticosteroids, or topical immunomodulatory treatments as needed), as dry skin is one of the predominant manifestations of AE. The purpose of emollients is to improve the skin barrier by restoring and maintaining skin hydration, therefore soothing the skin and reducing pruritus. Emollients are also a crucial element of maintenance treatment, and in the prevention of flares. Adults require at least 500g/per week and children at least 250g/per week. Pump dispensers are preferable in order to prevent contamination. The use of emollient wash products instead of ordinary soaps and bubble baths are also recommended. Bathing should be limited to short periods of time (ie, five-to-10 minutes) with warm water, and when finished, followed by application of emollients.
The British Association of Dermatologists (BAD) provides a caution in its patient information leaflet on atopic eczema regarding emollients and fire risk. According to BAD, in the leaflet: “Emollients, creams, lotions and ointments contain oils which can catch fire. When emollient products get in contact with dressings, clothing, bed linen or hair, there is a danger that a naked flame or cigarette smoking could cause these to catch fire. To reduce the fire risk, patients using skincare or haircare products are advised to be very careful near naked flames to reduce the risk of clothing, hair or bedding catching fire. In particular, smoking cigarettes should be avoided and being near people who are smoking or using naked flames, especially in bed. Candles may also risk fire. It is advisable to wash clothing daily which is in contact with emollients and bed linen regularly.”
Wet-wrapping treatment is a technique used in people with moderate-to-severe eczema by using two layers of open-weave tubular bandage applied over emollients. The bottom layer is soaked in warm water, squeezed out and then put onto the skin over the emollient wet and then followed by the top layer, which is dry. This treatment is reported to introduce moisture, soothe, and protect irritated skin from damage caused by scratching and is applied for short periods of time.
Caution should be taken when wet-wrapping using topical steroids, as absorption is increased. Occlusive medicated dressings or dry bandages should not be used in infected AE.
Topical corticosteroids are recognised as first-line anti-inflammatory treatment in acute exacerbations, and selection of agent varies depending on potency, the location and severity of skin affected by AE, patient age, and formulation. Topical corticosteroids are grouped into classes depending on their potency, ranging from mild, moderate, potent, to very potent. A fingertip unit (FTU) is a useful method for individuals to apply topical corticosteroid in safe quantities. FTU refers to the amount of ointment or cream applied from the end of an adult index fingertip to the distal crease (first joint) in the finger, and is equivalent to approximately 0.5 grams.
The recommended FTU of topical corticosteroid will depend on the part of the body being treated and whether the patient is an adult or child. The Irish Skin Foundation (ISF) has a useful guide describing the number of FTUs required for different parts of the body in adults and children in the eczema booklet at https://irishskin.ie/eczema/.
Topical calcineurin inhibitors (TCI) are considered as a second-line option for short-term and intermittent treatment of AE. These non-steroidal, anti-inflammatory agents do not cause skin atrophy and are beneficial in treating sensitive skin areas, such as the face and groin. Stinging on application is the most common side-effect, but this usually settles within a few days; also, sun protection is advised in patients treated with TCI.
Some patients and/or their carers may find application of topicals time-consuming and inconvenient, fear side-effects, and some treatments can be greasy in application.
Due to these factors, patients’ adherence to topical therapy can be suboptimal. It is important that patients and/or their carers are educated with verbal and written instructions to support the safe and successful use of these treatments in the long term and to set realistic expectations.
Phototherapy is a form of artificial ultraviolet light treatment, comprised of either ultraviolet A (UVA) or ultraviolet B (UVB) wavelengths of light, delivered in hospital dermatology day care centres. Narrow-band UVB is the most common type of phototherapy used to treat AE and is usually given three times a week. Another form of phototherapy that may be prescribed is PUVA. UVA must be combined with a light-sensitising medication such as psoralen to be effective, which is commonly known as PUVA, and this is given twice a week. Phototherapy may be given in combination with topical steroids and emollients to prevent flare-up.
Oral glucocorticosteroids may be prescribed for an acute flare of AE in unique cases and sometimes, in exceptional circumstances, as a short-term bridge therapy while initiating another systemic treatment. However, long-term use is not recommended in patients with AE.
Oral antihistamines may be prescribed for short-term and intermittent use in circumstances caused by intense pruritus during a flare.
In circumstances where AE is moderate-to-severe or widespread and has not responded to topical or phototherapy treatments, or when quality of life is significantly impacted, systemic immunosuppressive treatments may be prescribed. Current options include methotrexate, ciclosporin, mycophenolate mofetil, and azathioprine. The individual patient profile, lifestyle factors, associated comorbidities, side-effect profile, along with patient preference, all influence choice of drug. These medications have different toxicity profiles, therefore patients are reviewed and monitored regularly to avoid any potential side-effects.
Dupilumab is a monoclonal antibody that inhibits signalling of interleukin (IL)-4 and IL-13, two particular interleukins thought to play a role in AE development. Positive results in improved clinical and symptomatic outcomes have been reported in several clinical studies in the treatment for moderate-to-severe atopic eczema in adult patients. Dupilumab received regulatory approval in September 2017 from the European Medicines Agency (EMA). It is not currently reimbursed in the Republic of Ireland, but is available to people living in Northern Ireland through the NHS. There are also other biologic treatments for AE, which are currently undergoing research globally.
Taking a careful history to help identify any relationship between suspected triggers and AE skin symptoms is important. Identification, elimination and/or control of exacerbating triggers, such as physical and chemical irritants and environmental allergies, is helpful in preventing recurrent symptoms and disease deterioration. Consideration for non-allergic triggers may include psychological stress, temperature extremes, and dry, wintery or conditioned air.
Due to a weakened skin barrier, trauma from scratching and impaired cellular immunity, AE is often complicated by bacterial, viral, and fungal infections. Staphylococcus aureus is the most common organism to cause bacterial infection in AE. Distinctive signs may include honey-coloured crusts, weeping and pustules, and folliculitis in hair-bearing areas. Topical or oral antimicrobials may be prescribed. Bleach baths may be recommended in patients with moderate-to-severe AE with frequent bacterial infections.
Common viral infections seen in individuals with AE include Molluscum contagiosum, cutaneous warts and herpes simplex virus. The herpes simplex virus is reported in 3 per cent of patients and if not treated early, may cause systemic complications such as Eczema herpeticum. Usually, the infection is localised to the face and limbs and may present with grouped vesicles and/or pustules, which may progress to superficial erosions and crusting. This infection can spread quickly and responds well to oral antivirals or systemic antiviral therapy if fever or systemic symptoms are present.
AE is often referred to as the ‘itch that rashes’ due to the pruritus that patients with AE often experience. The urge to scratch can be overwhelming but only provides temporary relief, leading to more itching and scratching (the itch-scratch cycle), which may lead to excoriation and skin barrier damage. Itch interferes with sleep and negatively impacts on an individual’s quality-of-life, as well as that of the wider family, with sleep deprivation contributing to difficulties concentrating at school and/or work. Sufficient sleep is crucial for health and wellbeing.
In children, both acute and chronic sleep disruption have been associated with a range of cognitive, mood and behavioural impairments, as well as poor performance in school. In an ISF Living with Atopic Eczema Survey in 2019, respondents reported interrupted/loss of sleep in 86 per cent of children and 84 per cent of adults. Additionally, 26 per cent of carers of children with AE reported that their child missed one-to-two days of school per month due to their skin condition.
AE is associated with allergic comorbidities such as food allergy, allergic rhinitis and asthma, along with an increased risk of irritant and allergic contact dermatitis. However, less is known about AE’s possible association with non-allergic comorbidities, among which include: Extra-cutaneous infections; obesity; cardiovascular disease; alopecia, gastrointestinal immune-mediated disorders; and adult lymphomas (the latter has been associated with severe long-term AE).
For some, the burden of AE often extends beyond the immediate dermatological effects of this disease. AE can place a serious mental health burden on patients, particularly those living with moderate-to-severe disease, with research indicating that the more severe the AE, the more quality-of-life is impacted. It has been associated with anxiety, depression, and attention deficit hyperactivity disorder. Research has indicated that the health-related quality-of-life in children with AE is comparable to that of other chronic childhood diseases, such as diabetes or asthma.
AE is often associated as a disease of childhood, but it is important not to forget that AE can be a very distressing condition for adults as well. While severity of AE varies greatly, most are affected by mild disease. Due to a variety of treatments for AE and different individual symptoms, it is important to educate patients and their families about the disease, and self-care to ensure compliance and effective management. These include basic skin care routines that fit in with the individual’s lifestyle, management of future flares and trigger avoidance.
Also, consideration around any potential fears with regards to side-effects of medications such as topical steroids should be addressed, as this may impede sufficient treatment. Education for self-managing AE is reported to improve the severity of the disease and also improve the quality-of-life for these individuals and their carers.
National Eczema Week took place on 13-19 September 2020. Information and resources for people with atopic eczema and their carers is available on the ISF website, www.irishskin.ie. The charity also operates an ‘Ask a Nurse’ Helpline on (01) 486-6280 with access to specialist dermatology nurses, who provide one-to-one guidance about a range of skin conditions.
The Judge's report proposes that a Tribunal be established under legislation to hear and determine claims...
In December, the HSE released part of an external review into the case of 'Brandon', a...
The evidence on doctor burnout “should scare us and concern us”, the Director of the RCSI...
A review of public health governance structures and addressing “longstanding” IT infrastructure...